Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
Clinical trial NCT02911142 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02911142
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-07-03
- Primary completion
- 2024-10-01
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.